Skip to main content
Livermore
Livermore
中文EN

Gritstone bio, Inc.

GRTSDelisted Mar 5, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001656634

Gritstone bio, Inc. was delisted on Mar 5, 2025; its insiders filed their last Form 4 on Apr 8, 2025; 56 institutions reported holding it in 13F filings for Q3 2024, worth $20.7M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Gritstone bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Gritstone bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Gritstone bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Jones Elaine VDirector–Apr 8, 20250
Webster Stephen WDirector0Apr 8, 20250
Rizvi NaiyerDirector–Apr 8, 20250
Agarwal ShefaliDirector–Apr 8, 20250
Economides VassilikiEVP, CHIEF FINANCIAL OFFICER0Apr 8, 20250
Cho JamesSVP, CHIEF ACCOUNTING OFFICER0Apr 8, 20250
Fisher ClareDirector–Apr 8, 20250
Corey LawrenceDirector–Apr 8, 20250
Allen Andrew RPRESIDENT AND CEO985,360Jun 26, 20240
Jones ErinEVP, CHIEF OPERATING OFFICER359,293May 17, 20240
Jooss KarinSEE REMARKS683,526May 17, 20240
Hawryluk MatthewEVP, CHIEF BUSINESS OFFICER313,931May 17, 20240
Krognes Steve E.Director–Jun 21, 20230
Heyman Richard A.Director–Jun 22, 20220
Thompson RahsaanEVP and General Counsel58,698Apr 20, 20220
Li JudithDirector–Nov 19, 20210
Rousseau RaphaelSee Remarks29,700Nov 19, 20210
Yelensky RomanSee Remarks234,672Nov 19, 20210
Yabannavar VijaySee Remarks31,696Nov 19, 20210
Woiwode ThomasDirector128Aug 27, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 20, 2024 (view filing)4:15 PM ETDec 182 daysEconomides VassilikiEVP, CHIEF FINANCIAL OFFICERSSale−12.0K$0.015−$180−4.6%250.4K after
May 17, 2024 (view filing)May 161 dayAllen Andrew RPRESIDENT AND CEOSSale−24.3K$0.75−$18.2K−2.4%985.4K after
May 17, 2024 (view filing)May 161 dayJones ErinEVP, CHIEF OPERATING OFFICERSSale−13.7K$0.75−$10.3K−3.7%359.3K after
May 17, 2024 (view filing)May 161 dayJooss KarinSEE REMARKSSSale−13.7K$0.75−$10.3K−2.0%683.5K after
May 17, 2024 (view filing)May 161 dayHawryluk MatthewEVP, CHIEF BUSINESS OFFICERSSale−9.26K$0.75−$6.94K−2.9%313.9K after
May 17, 2024 (view filing)May 161 dayEconomides VassilikiEVP, CHIEF FINANCIAL OFFICERSSale−13.7K$0.75−$10.3K−5.0%262.4K after
May 24, 2023 (view filing)May 231 dayEconomides VassilikiSee RemarksPPurchase+12.0K$1.90+$22.8K+5.9%214.1K after
Dec 3, 2021 (view filing)4:47 PM ETDec 12 daysJones ErinChief Operating OfficerSSale−1.00K$13.01−$13.0K−2.1%45.9K after
Dec 3, 2021 (view filing)4:45 PM ETNov 132 daysJones ErinChief Operating OfficerSSale−1.00K$11.14−$11.1K−2.1%45.9K afterAmended
Dec 3, 2021 (view filing)4:43 PM ETOct 1-463 daysJones ErinSee RemarksSSale−2.00K$10.70−$21.4K−4.2%45.9K afterAmended2 lots
Nov 19, 2021 (view filing)6:01 PM ETSep 872 daysJones ErinSee RemarksSSale−2.00K$11.37−$22.7K−4.2%45.9K afterAmended
Nov 19, 2021 (view filing)Jan 19304 daysYelensky RomanSee RemarksSSale−10.0K$22.10−$221.0K−5.9%160.6K afterAmended